Which has preferable earnings & valuation, AVLN or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$22.81 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is AVLN or RLMD more profitable?

Avalyn Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Relmada Therapeutics N/A -47.52% -43.97%

Does the media prefer AVLN or RLMD?

In the previous week, Relmada Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 9 mentions for Relmada Therapeutics and 7 mentions for Avalyn Pharma. Relmada Therapeutics' average media sentiment score of 1.62 beat Avalyn Pharma's score of 0.68 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RLMD or ETON?

In the previous week, Relmada Therapeutics had 7 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 9 mentions for Relmada Therapeutics and 2 mentions for Eton Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.62 beat Eton Pharmaceuticals' score of 1.20 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIP or RLMD?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 9 articles in the media. Relmada Therapeutics' average media sentiment score of 1.62 beat ANI Pharmaceuticals' score of 0.73 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, LBRX or RLMD?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is LBRX or RLMD more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Relmada Therapeutics N/A -47.52% -43.97%

Does the media prefer LBRX or RLMD?

In the previous week, Relmada Therapeutics had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Relmada Therapeutics and 4 mentions for LB Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.62 beat LB Pharmaceuticals' score of 1.26 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor RLMD or XERS?

In the previous week, Relmada Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Relmada Therapeutics and 6 mentions for Xeris Biopharma. Relmada Therapeutics' average media sentiment score of 1.62 beat Xeris Biopharma's score of 0.64 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xeris Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$4.52 +0.45 (+11.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.56 +0.04 (+0.97%)

As of 09/11/2026 07:59 PM Eastern

Compare

RLMD vs. AVLN, ETON, ANIP, LBRX, and XERS

Should you buy Relmada Therapeutics stock or one of its competitors? Relmada Therapeutics's main competitors and comparable companies include Avalyn Pharma (AVLN), Eton Pharmaceuticals (ETON), ANI Pharmaceuticals (ANIP), LB Pharmaceuticals (LBRX), and Xeris Biopharma (XERS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Relmada Therapeutics compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, Relmada Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 9 mentions for Relmada Therapeutics and 7 mentions for Avalyn Pharma. Relmada Therapeutics' average media sentiment score of 1.62 beat Avalyn Pharma's score of 0.68 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Avalyn Pharma presently has a consensus target price of $60.00, suggesting a potential upside of 78.73%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 165.49%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Relmada Therapeutics	N/A	-47.52%	-43.97%

Summary

Relmada Therapeutics beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

How does Relmada Therapeutics compare to Eton Pharmaceuticals?

Relmada Therapeutics (NASDAQ:RLMD) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Relmada Therapeutics had 7 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 9 mentions for Relmada Therapeutics and 2 mentions for Eton Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.62 beat Eton Pharmaceuticals' score of 1.20 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a net margin of 12.02% compared to Relmada Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Relmada Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Eton Pharmaceuticals	$79.95M	20.40	-$4.60M	$0.38	150.21

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 165.49%. Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 18.26%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Eton Pharmaceuticals beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.83	$78.34M	$4.64	15.13
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 9 articles in the media. Relmada Therapeutics' average media sentiment score of 1.62 beat ANI Pharmaceuticals' score of 0.73 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ANI Pharmaceuticals has a net margin of 11.07% compared to Relmada Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Relmada Therapeutics	N/A	-47.52%	-43.97%

ANI Pharmaceuticals presently has a consensus price target of $105.57, indicating a potential upside of 50.41%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 165.49%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

ANI Pharmaceuticals beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Relmada Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Relmada Therapeutics had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 9 mentions for Relmada Therapeutics and 4 mentions for LB Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.62 beat LB Pharmaceuticals' score of 1.26 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LB Pharmaceuticals' return on equity of -25.92% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Relmada Therapeutics	N/A	-47.52%	-43.97%

LB Pharmaceuticals currently has a consensus target price of $49.63, indicating a potential upside of 11.19%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 165.49%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Relmada Therapeutics beats LB Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Relmada Therapeutics compare to Xeris Biopharma?

Relmada Therapeutics (NASDAQ:RLMD) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 165.49%. Xeris Biopharma has a consensus target price of $12.80, indicating a potential upside of 71.81%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Relmada Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has higher revenue and earnings than Relmada Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Xeris Biopharma	$291.85M	4.65	$550K	-$0.11	N/A

Relmada Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Relmada Therapeutics and 6 mentions for Xeris Biopharma. Relmada Therapeutics' average media sentiment score of 1.62 beat Xeris Biopharma's score of 0.64 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xeris Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Xeris Biopharma	-5.12%	338.21%	3.50%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Relmada Therapeutics beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$482.15M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-5.02	799.75	274.94	25.36
Price / Sales	N/A	960.74	685.44	117.05
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	3.83	10.39	10.33	6.20
Net Income	-$57.38M	$2.85B	$3.50B	$358.50M
7 Day Performance	2.03%	-3.61%	-3.32%	-2.35%
1 Month Performance	-4.84%	0.72%	-0.53%	-3.23%
1 Year Performance	184.28%	3.61%	23.51%	8.79%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.9346 of 5 stars	$4.52 +11.1%	$12.00 +165.5%	+184.3%	$482.15M	N/A	N/A	10	News Coverage Positive News Insider Trade Gap Up High Trading Volume
AVLN Avalyn Pharma	3.5357 of 5 stars	$38.35 +2.6%	$60.00 +56.5%	N/A	$1.70B	N/A	N/A	51	News Coverage Positive News Analyst Upgrade
ETON Eton Pharmaceuticals	4.4069 of 5 stars	$59.01 +1.0%	$67.50 +14.4%	+223.4%	$1.69B	$79.95M	155.68	20	Positive News
ANIP ANI Pharmaceuticals	4.0226 of 5 stars	$70.89 -0.5%	$105.83 +49.3%	-28.2%	$1.63B	$883.37M	15.28	600	Analyst Forecast
LBRX LB Pharmaceuticals	1.7666 of 5 stars	$48.65 -1.4%	$49.63 +2.0%	N/A	$1.57B	N/A	N/A	16

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. AVLN, ETON, ANIP, LBRX, and XERS

How does Relmada Therapeutics compare to Avalyn Pharma?

Summary

How does Relmada Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to LB Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. AVLN, ETON, ANIP, LBRX, and XERS

How does Relmada Therapeutics compare to Avalyn Pharma?

Does the media prefer AVLN or RLMD?

Do analysts recommend AVLN or RLMD?

Which has preferable earnings & valuation, AVLN or RLMD?

Do institutionals and insiders hold more shares of AVLN or RLMD?

Is AVLN or RLMD more profitable?

Summary

How does Relmada Therapeutics compare to Eton Pharmaceuticals?

Does the media prefer RLMD or ETON?

Is RLMD or ETON more profitable?

Which has more risk & volatility, RLMD or ETON?

Do institutionals & insiders have more ownership in RLMD or ETON?

Which has higher earnings and valuation, RLMD or ETON?

Do analysts prefer RLMD or ETON?

Summary

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Which has more risk & volatility, ANIP or RLMD?

Which has higher valuation & earnings, ANIP or RLMD?

Do institutionals and insiders have more ownership in ANIP or RLMD?

Does the media prefer ANIP or RLMD?

Is ANIP or RLMD more profitable?

Do analysts recommend ANIP or RLMD?

Summary

How does Relmada Therapeutics compare to LB Pharmaceuticals?

Does the media prefer LBRX or RLMD?

Is LBRX or RLMD more profitable?

Do analysts rate LBRX or RLMD?

Which has higher earnings & valuation, LBRX or RLMD?

Do institutionals & insiders have more ownership in LBRX or RLMD?

Summary

How does Relmada Therapeutics compare to Xeris Biopharma?

Do analysts rate RLMD or XERS?

Which has higher earnings & valuation, RLMD or XERS?

Which has more volatility & risk, RLMD or XERS?

Does the media favor RLMD or XERS?

Is RLMD or XERS more profitable?

Do institutionals and insiders believe in RLMD or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools